CHASE questionnaire
exploratorybiomarker · high
Quantify owner-assessed clinical signs of Chiari-like malformation and syringomyelia-associated neuropathic pain and itch in dogs and distinguish treatment response.
Owner questionnaire validated in healthy and CM/SM-affected dogs, including a double-blinded randomized crossover study using pregabalin and placebo with CHASE as the primary outcome.
2026 Journal of Veterinary Internal Medicine publication validating the CHASE questionnaire.
CHASE scores distinguished CM/SM-affected dogs from healthy dogs, showed strong internal consistency, and decreased significantly with pregabalin compared with baseline and placebo.
Felycin-CA1
approveddrug program · medium
Treat ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy.
Conditionally approved veterinary therapeutic; site analysis links TriviumVet's approach to mTOR inhibition and sirolimus/rapamycin programs.
Listed as conditionally approved for ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy.
A related feline HCM rapamycin pilot study reported once-weekly delayed-release oral rapamycin was safe and well tolerated over eight weeks and showed transcriptomic/proteomic signals consistent with reduced myocardial hypertrophy and autophagy activation.
HALT Study
undisclosedresearch program · low
Undisclosed TriviumVet pipeline-listed study; objective not specified in supplied material.
Study listed in TriviumVet pipeline material; no protocol details supplied.
Listed in TriviumVet pipeline_listed field.
Low-dose delayed-release rapamycin for feline cardiogenic arterial thromboembolism prevention
preclinicaldrug program · high
Evaluate whether low-dose delayed-release rapamycin can reduce platelet activation and procoagulant platelet phenotypes relevant to cardiogenic arterial thromboembolism in cats.
Domestic cats received 0.3 mg/kg low-dose delayed-release rapamycin orally every 7 days for 4 weeks; ex vivo platelet aggregation, P-selectin, mitochondrial membrane potential, and phosphatidylserine exposure were assessed.
2026 Scientific Reports publication of ex vivo platelet effects in domestic cats.
Rapamycin did not affect aggregation but reduced P-selectin expression in some agonist/timepoint samples, protected mitochondrial membrane potential across agonists and times, and reduced phosphatidylserine exposure at 24 hours in thrombin samples.
Preclinical enteropathy biomarker study in soft-coated wheaten terriers
exploratoryresearch program · high
Identify early biomarker changes associated with preclinical inflammatory bowel disease or protein-losing enteropathy risk in soft-coated wheaten terriers.
Prospective study comparing healthy soft-coated wheaten terriers, healthy non-SCWT dogs, and PLE dogs using fecal calprotectin, targeted fecal metabolites, unconjugated bile acids, intestinal permeability testing, and video capsule endoscopy.
2025 Journal of Veterinary Internal Medicine publication on preclinical enteropathy in healthy soft-coated wheaten terriers.
Healthy SCWT dogs showed changes in several biomarkers used to identify preclinical IBD in humans, including group differences in fecal fatty acids and sterols and intestinal permeability patterns closer to PLE dogs than healthy non-SCWT dogs.
RAPASAS Study
undisclosedresearch program · low
Undisclosed TriviumVet pipeline-listed study; objective not specified in supplied material.
Study listed in TriviumVet pipeline material; name suggests a rapamycin-related study, but supplied material does not define the protocol.
Listed in TriviumVet pipeline_listed field.
REPAIR Study
undisclosedresearch program · low
Undisclosed TriviumVet pipeline-listed study; objective not specified in supplied material.
Study listed in TriviumVet pipeline material; no protocol details supplied.
Listed in TriviumVet pipeline_listed field.
REVERSE Study
undisclosedresearch program · low
Undisclosed TriviumVet pipeline-listed study; objective not specified in supplied material.
Study listed in TriviumVet pipeline material; no protocol details supplied.
Listed in TriviumVet pipeline_listed field.
The Dog Aging Project
exploratoryresearch program · low
Research program related to dog aging; TriviumVet pipeline material lists it among programs/studies.
Dog aging research program; supplied material does not provide TriviumVet-specific protocol details.
Listed in TriviumVet pipeline_listed field.
TriviumVet 10 mg omeprazole capsule for dogs
undiscloseddrug program · medium
Increase gastric pH in dogs for potential treatment of acid-related gastrointestinal conditions such as esophagitis and duodenal ulceration.
Prospective randomized masked placebo-controlled 2-way crossover study of 10 mg enteric-coated omeprazole capsules administered orally twice daily to healthy dogs for 5 days with intragastric pH monitoring.
Published prospective crossover gastric pH study; publication abstract states the TriviumVet capsule was undergoing FDA approval.
The supplied abstract states the study evaluated whether encapsulated omeprazole significantly increased gastric pH compared with placebo, but the provided material is truncated before final efficacy results.
